• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice


ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

Michael Koren, MD, primary investigator for the V-INITIATE study that was presented at the American College of Cardiology Annual Scientific Sessions in Atlanta, GA, over the weekend, spoke with Patient Care© about the rationale for the study, highlighting the need to find better ways to ensure individuals with ASCVD reach LDL-C targets and shared the remarkable findings.

"So what we were asking in this study was how can we do better treating cholesterol issues in people with cardiovascular disease? Because the sad reality is that very few of our patients who have atherosclerotic cardiovascular disease reach the guideline recommended goals for LDL-C. Why are we doing so poorly and how can we do better?" He explains further in this conversation.

Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study, is a cardiologist and serves as the chief executive officer at ENCORE Research Group, in Jacksonville, FL. Koren founded ENCORE in 1997 and since then the organization has conducted more than 2500 clinical trials across 8 locations in Florida.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.